13F filerCIK 1061768 ↗

Baupost Group

You are looking at Q1 2018. See the latest, Q3 2026 →

Reported value

$10.37B

+2.5% on the quarter before

Positions

33

2 new, 3 sold out

Top 10

76.5%

of the value

Est. gain

−$325.7M

on stocks held all quarter

Est. return

−3.3%

on those stocks since Q4 2017

Filed

May 14, 2018

On SEC EDGAR ↗

Positions as of Mar 31, 2018, from Baupost Group's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.

Portfolio at a glance

  • New
  • Added
  • Cut
  • Same
  • Options

Each tile is a position, sized by its share, colored by what the fund did with it since Q4 2017. Striped tiles are options.

Cheniere Energy Inc11%
Synchrony Finl9.5%
Twenty First Centy Fox Inc9.4%
Viasat Inc8.7%
Allergan Plc7.7%
Qorvo7.5%
Time Warner Inc7.4%
Pioneer Nat Res Co6.6%
Antero Res Corp5.1%
Twenty First Centy Fox Inc4.0%
Cardinal Health Inc3.1%
Colony Northstar Inc2.7%
Pbf Energy Inc2.6%
Atara Biotherapeutics Inc2.4%
Mckesson Corp2.2%
Theravance Biopharma Inc2.2%
Veritiv Corp1.4%
Pg&E Corp1.3%
9 others1.3%
Amerisourcebergen Corp1.1%
Keryx Biopharmaceuticals Inc1.0%
0.7%
0.6%
0.5%

Largest buys

Since Q4 2017, sized at quarter-end prices.

  1. Pioneer Nat Res Co~$343.6MAdded, 3.4% → 6.6% of the portfolio+2,000,000 shares
  2. Twenty First Centy Fox Inc~$157.8MAdded, 7.6% → 9.4% of the portfolio+4,300,000 shares
  3. Pg&E Corp~$138.4MNew, 0.0% → 1.3% of the portfolio+3,149,972 shares
  4. Tesla~$52.2MNew, 0.0% → 0.5% of the portfolio+50,000,000 shares
  5. Allergan Plc~$42.1MAdded, 7.3% → 7.7% of the portfolio+250,000 shares
  6. Antero Res Corp~$37.0MAdded, 4.6% → 5.1% of the portfolio+1,865,604 shares
  7. Mckesson Corp~$36.0MAdded, 2.1% → 2.2% of the portfolio+255,700 shares
  8. Atara Biotherapeutics Inc~$34.9MAdded, 1.0% → 2.4% of the portfolio+895,000 shares
  9. Viasat Inc~$32.9MAdded, 9.7% → 8.7% of the portfolio+500,000 shares
  10. Twenty First Centy Fox Inc~$32.8MAdded, 3.6% → 4.0% of the portfolio+902,100 shares

Largest sells

Since Q4 2017, sized at quarter-end prices.

  1. Express Scripts Hldg Co~$172.2MSold out, 1.7% → 0.0% of the portfolio−2,306,456 shares
  2. Pbf Energy Inc~$101.7MCut, 3.8% → 2.6% of the portfolio−3,000,000 shares
  3. Cascadian Therapeutics Inc~$32.3MSold out, 0.3% → 0.0% of the portfolio−8,721,079 shares
  4. Sunrun Inc~$16.8MSold out, 0.2% → 0.0% of the portfolio−2,848,082 shares
  5. Amerisourcebergen Corp~$10.1MCut, 1.3% → 1.1% of the portfolio−117,349 shares
  6. ChipMOS Technologies~$8.5MCut, 0.3% → 0.1% of the portfolio−536,750 shares
  7. Forward Pharma A/S~$2.9MCut, 0.2% → 0.1% of the portfolio−1,331,937 shares

Holdings

As of Mar 31, 2018; changes in shares since Dec 31, 2017.

Positions, sorted by share of the portfolio
HoldingValue
Cheniere Energy IncCOM NEW · shares 0% · price −0.7%10.7%$1.11B−$8.1M
Synchrony FinlCOM · shares 0% · price −13.2%9.5%$982.3M−$148.8M
Twenty First Centy Fox IncCL A · shares +19% · price +6.3%9.4%$975.5M+$48.1M
Viasat IncCOM · shares +3.8% · price −12.2%8.7%$897.6M−$120.1M
Allergan PlcSHS · shares +5.6% · price +2.9%7.7%$799.4M+$21.2M
QorvoCOM · shares 0% · price +5.8%7.5%$775.0M+$42.4M
Time Warner IncCOM NEW · shares 0% · price +3.4%7.4%$766.1M+$25.2M
Pioneer Nat Res CoCOM · shares +100% · price −0.6%6.6%$687.1M−$2.1M
Antero Res CorpCOM · shares +7.5% · price +4.5%5.1%$527.8M+$21.0M
Twenty First Centy Fox IncCL B · shares +8.6% · price +6.6%4.0%$415.8M+$23.7M
Cardinal Health IncCOM · shares 0% · price +2.3%3.1%$319.7M+$7.2M
Colony Northstar IncCL A COM · shares +3.7% · price −50.7%2.7%$279.2M−$277.4M
Pbf Energy IncCL A · shares −27% · price −4.4%2.6%$268.6M−$12.3M
Atara Biotherapeutics IncCOM · shares +17% · price +115.5%2.4%$243.9M+$112.0M
Mckesson CorpCOM · shares +19% · price −9.7%2.2%$227.6M−$20.5M
Theravance Biopharma IncCOM · shares 0% · price −13.1%2.2%$225.7M−$33.9M
Veritiv CorpCOM · shares +5.0% · price +35.6%1.4%$149.9M+$37.5M
Pg&E CorpCOM · shares New1.3%$138.4M—
Amerisourcebergen CorpCOM · shares −8.2% · price −6.1%1.1%$113.6M−$7.4M
Keryx Biopharmaceuticals IncCOM · shares 0% · price −12.0%1.0%$105.5M−$14.4M
Amc Entmt Hldgs IncCL A COM · shares 0% · price −7.0%0.68%$70.3M−$5.2M
Novagold Res IncCOM NEW · shares +25% · price +10.2%0.56%$58.3M+$4.3M
TeslaNOTE 2.375% 3/1 · shares New0.50%$52.2M—
Gty Technology Holdings IncUNIT 99/99/9999 · shares 0% · price +0.4%0.44%$45.5M+$161,000
Paratek Pharmaceuticals IncCOM · shares 0% · price −27.4%0.30%$31.1M−$11.7M
Total 33 positions100%$10.37B−$325.7M

Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.

What made money

From Q4 2017 to Q1 2018: 30 stocks held throughout, down $325.7M (−3.3%).

  1. Atara Biotherapeutics Inc+$112.0M+115%
  2. Twenty First Centy Fox Inc+$48.1M+6%
  3. Qorvo+$42.4M+6%
  4. Veritiv Corp+$37.5M+36%
  5. Time Warner Inc+$25.2M+3%
  6. Mckesson Corp−$20.5M−10%
  7. Theravance Biopharma Inc−$33.9M−13%
  8. Viasat Inc−$120.1M−12%
  9. Synchrony Finl−$148.8M−13%
  10. Colony Northstar Inc−$277.4M−51%

Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.

Reported value by quarter

Pick a quarter to see what the fund held then.

$20.00B$10.00B$0
Q1 2016Q3 2026
Every quarter's filing
Each quarter's 13F filing, newest first
QuarterReported valueFiling
Q3 2026$5.05B−7%SEC ↗
Q2 2026$5.42B+6%SEC ↗
Q1 2026$5.12B−3%SEC ↗
Q4 2025$5.28B+10%SEC ↗
Q3 2025$4.79B+16%SEC ↗
Q2 2025$4.13B+18%SEC ↗
Q1 2025$3.50B+2%SEC ↗
Q4 2024$3.43B−2%SEC ↗
Q3 2024$3.52B−3%SEC ↗
Q2 2024$3.63B−0%SEC ↗
Q1 2024$3.65B−20%SEC ↗
Q4 2023$4.59B−12%SEC ↗
Q3 2023$5.21B−7%SEC ↗
Q2 2023$5.61B−4%SEC ↗
Q1 2023$5.85B−5%SEC ↗
Q4 2022$6.13B+6%SEC ↗
Q3 2022$5.79B−14%SEC ↗
Q2 2022$6.77B−27%SEC ↗
Q1 2022$9.30B−8%SEC ↗
Q4 2021$10.13B−7%SEC ↗
Q3 2021$10.88B−12%SEC ↗
Q2 2021$12.33B−2%SEC ↗
Q1 2021$12.56B+16%SEC ↗
Q4 2020$10.84B+17%SEC ↗
Q3 2020$9.25B+15%SEC ↗
Q2 2020$8.01B+18%SEC ↗
Q1 2020$6.77B−25%SEC ↗
Q4 2019$9.06B+3%SEC ↗
Q3 2019$8.83B−20%SEC ↗
Q2 2019$11.05B−7%SEC ↗
Q1 2019$11.90B+3%SEC ↗
Q4 2018$11.52B−12%SEC ↗
Q3 2018$13.06B+14%SEC ↗
Q2 2018$11.44B+10%SEC ↗
Q1 2018$10.37B+3%SEC ↗
Q4 2017$10.11B+26%SEC ↗
Q3 2017$8.02B−8%SEC ↗
Q2 2017$8.75B+3%SEC ↗
Q1 2017$8.49B+11%SEC ↗
Q4 2016$7.67B+9%SEC ↗
Q3 2016$7.04B−4%SEC ↗
Q2 2016$7.37B+6%SEC ↗
Q1 2016$6.92BSEC ↗

Subscribe to TheInference for free